Drug Discovery Weekly — 2026-04-03
The FDA made headlines this week with the approval of Foundayo (orforglipron) as the first new molecular entity under the Commissioner's National Priority Voucher program, while the agency also extended its review timeline for Orca-T in hematologic malignancies. On the clinical front, a Phase 3 trial confirmed that durvalumab plus chemotherapy delivers meaningful survival benefits in advanced biliary tract cancer. Meanwhile, biotech licensing deal activity continues to accelerate in 2026, with average deal sizes already up 76% year-over-year.
Drug Discovery Weekly — 2026-04-03
FDA & Regulatory Decisions
1. Foundayo (orforglipron) — FDA First NME Approval Under National Priority Voucher Program
The U.S. Food and Drug Administration approved Foundayo (orforglipron) on April 1, 2026, marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program. This milestone is notable as the first new molecular entity (NME) to earn approval under this initiative.
2. Orca-T — FDA Extends Review Period for Hematologic Malignancies
The FDA has extended the PDUFA action date for Orca-T to July 6, 2026, for its potential approval across multiple hematologic malignancies. The extension gives the agency additional time to evaluate the engineered T-cell therapy.
3. Vertex Secures Broader Labels for Alyftrek and Trikafta
Vertex Pharmaceuticals secured expanded FDA labeling for its cystic fibrosis medications Alyftrek and Trikafta in early 2026, broadening the eligible patient population for these CFTR modulator therapies. Fierce Pharma's regulatory tracker for the first half of 2026 documents ongoing label expansions across key geographies and new indications.
Clinical Trial Spotlight
1. Durvalumab + Chemotherapy in Advanced Biliary Tract Cancer — Meaningful Survival Benefit
A first-line combination of durvalumab (Imfinzi, AstraZeneca) with chemotherapy produced a clinically meaningful and statistically significant overall survival benefit in patients with advanced biliary tract cancer, according to data published within the past 24 hours. The results reinforce the immunotherapy combination as a viable standard-of-care option in this difficult-to-treat indication.
2. Transdermal Estradiol Patch Meets Noninferiority Bar vs. LHRH Agonists in Prostate Cancer
A Phase 3 trial found that a transdermal estradiol patch is noninferior to standard LHRH agonist therapy in locally advanced prostate cancer. Key findings include fewer hot flashes, lower fracture rates — but a higher rate of gynecomastia — compared to the standard-of-care hormone therapy. The results open the door to a simpler, potentially better-tolerated alternative for prostate cancer hormone management.
3. Breast Cancer Immunotherapy Trials Show Modest Clinical Impact
A new study published this week reveals that despite numerous breast cancer immunotherapy trials, clinical impact has been modest — with only 2 approved drugs in this space. The research highlights systemic inefficiencies in the clinical trial system and calls for better patient selection and biomarker-driven approaches.
Deals & Partnerships
1. Biotech Licensing Deal Activity Surges 76% in Early 2026
Average biotech licensing deal size has reached $1.3 billion in early 2026 — a 76% increase over 2025 levels — driven by mega-licensing agreements involving China-originated assets and platform technologies, according to analysis from Vision Lifesciences. The firm's Biotech Licensing Deal Tracker for 2026 covers more than $250 billion in analyzed transactions and identifies a clear trend toward larger, fewer deals with greater strategic rationale.
2. BioMarin to Acquire Amicus Therapeutics for ~$4.8 Billion (Closing Expected Q2 2026)
BioMarin Pharmaceutical struck a definitive agreement to acquire Amicus Therapeutics in an all-cash deal valued at approximately $4.8 billion, or $14.50 per share, with the deal expected to close in Q2 2026. The acquisition bolsters BioMarin's rare disease portfolio with Amicus's enzyme replacement therapies. The deal was among the biggest biopharma M&A transactions of late 2025 and remains a key strategic event as it moves toward close.
Pipeline & Discovery Breakthroughs
1. AI-Discovered Drugs Enter Pivotal Phase 3 Era
2026 is shaping up to be a decisive moment for artificial intelligence in drug discovery. Over 173 AI-discovered drugs are now in clinical trials, with 15–20 entering pivotal Phase 3 this year — the industry's first real test of whether computational pipelines can deliver regulatory-ready data. The outcome will define the credibility and investment trajectory of AI-first drug discovery for the next decade.
2. Q2 2026 FDA Pipeline: Dato-DXd in TNBC and Orca-T in Blood Cancers
The second quarter of 2026 carries high-stakes FDA decisions that could transform oncology care. Dato-DXd (datopotamab deruxtecan), an antibody-drug conjugate being developed by AstraZeneca and Daiichi Sankyo, is under FDA review for triple-negative breast cancer (TNBC). Meanwhile, Orca-T's review timeline — now extended to July — remains one of the most closely watched regulatory decisions in hematology. These decisions are expected to significantly affect precision oncology and survival outcomes.
3. FDA Q1 2026 Oncology Approvals: Nine Total Including Blood Cancer and Pancreatic Cancer
In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic cancer, and more, according to the American Association for Cancer Research blog. This rate of oncology approvals reflects ongoing momentum in targeted and immunotherapy-based cancer treatments.
What to Watch Next Week
-
Orca-T (July 6, 2026 PDUFA Date) — Following this week's timeline extension, the hematology community will watch for any additional FDA information requests or advisory committee announcements regarding this engineered T-cell therapy for hematologic malignancies.
-
Dato-DXd FDA Decision for TNBC — AstraZeneca and Daiichi Sankyo's antibody-drug conjugate for triple-negative breast cancer is among the most closely watched Q2 2026 FDA decisions. Expect updated timelines and potential advisory committee dates to surface in the coming days.
-
AI Drug Discovery Phase 3 Readouts — With 15–20 AI-discovered compounds entering pivotal trials in 2026, early efficacy and safety data from these studies could begin emerging. Data readouts from companies including those partnered with Google would be watershed moments for computational drug discovery validation.
-
BioMarin / Amicus Therapeutics Deal Closing (Expected Q2 2026) — Regulatory approvals and shareholder votes for the $4.8 billion acquisition should advance next week, with the close expected in the coming months. Analysts will track any conditions or amendments.
-
March Oncology FDA Approvals Full Recap — OncLive's March roundup of four FDA oncology decisions is expected to gain additional analyst commentary and clinical response in the week ahead as prescribing physicians digest the new approvals.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Create your own signal
Describe what you want to know, and AI will curate it for you automatically.
Create SignalPowered by
